The future of HIV prevention

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue SUPPL. 2, 2012, Pages

  Padian, Nancy S ^a,b   Isbell, Michael T ^c   Russell, Elizabeth S ^d   Essex, M ^d  

^a US President's Emergency Plan for AIDS Relief   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Independent Health Policy Consultant   (United States)

^d Harvard AIDS Institute   (United States)

Author keywords

adherence; antiretrovirals; behavioral interventions; biomedical interventions; microbicides; prevention

Indexed keywords

ANTIRETROVIRUS AGENT; MICROBICIDE; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BEHAVIOR MODIFICATION; CIRCUMCISION; CONDOM; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; EPIDEMIC; EVIDENCE BASED MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; NONHUMAN; ORGANIZATION; PRIORITY JOURNAL; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUAL EDUCATION; SEXUAL TRANSMISSION; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREVENTIVE HEALTH SERVICES; RISK FACTORS; SEXUAL BEHAVIOR;

EID: 84864248424     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825b7100     Document Type: Article

References (51)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180. (Pubitemid 24331334)
2. World Health Organization (WHO), Joint United Nations Programme on HIV/AIDS (UNAIDS), UNICEF. Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access. Progress Report 2011. Geneva, Switzerland: WHO, UNAIDS, and UNICEF; 2011. Available at: http://www.afro.who. int/en/clusters-a-programmes/dpc/acquired-immune-deficiency-syndrome/features/ 3439-global-hivaidsresponse-progress-report-2011.html. Accessed February 15, 2012.
3. De Walque D, Dow WH, Nathan R, et al. Incentivising safe sex: a randomised trial of conditional cash transfers for HIV and sexually transmitted infection prevention in rural Tanzania. BMJ Open. 2012;2: e000747.
4. Baird S, Chirwa E, McIntosh C, et al. The short-term impacts of a schooling conditional cash transfer program on the sexual behavior of young women. Health Econ. 2010;19(suppl):55-68.
5. Baird SJ, Garfein RS, McIntosh CT, et al. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet. 2012;379: 1320-1329.
6. Kohler HP, Thornton RL. Conditional cash transfers and HIV/AIDS prevention: unconditionally promising? World Bank Econ Rev. 2012; 26:165-190.
7. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362: 2282-2294.
8. Cohen MS, Chen YQ, McCauley M, et al. Prevention of hiv-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365: 493-505.
9. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
10. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
11. Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study MOAX0106. Paper presented at: 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 17-20, 2011; Rome, Italy.
12. Thigpen M, Kebaabetswe P, Smith D, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study WELBC01. Paper presented at: 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 17-20, 2011; Rome, Italy.
13. Kashuba AD, Patterson KB, Dumond JB, et al. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet. 2011; published online ahead of print, DOI: 10.1016/S0140-6736(11)61852-7.
14. van der Straten A, van Damme L, Haberer J, et al. How well does PREP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS. 2012;26:F13-19.
15. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
16. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-656. (Pubitemid 46281312)
17. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007; 369:657-666.
18. Novitsky V, Ndung'u T, Wang R, et al. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS. 2011;25: 1515-1522.
19. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929. (Pubitemid 30177052)
20. Truong HH, Kellogg TA, McFarland W, et al. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One. 2011;6:e25281.
21. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-147. (Pubitemid 46089674)
22. UNAIDS. Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2010. Available at: http://www.unaids.org/en/resources/publications/ unaidspublications/2010/. Accessed February 15, 2012.
23. Jewkes RK, Dunkle K, Nduna M, et al. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet. 2010;376: 41-48.
24. Maman S, Mbwambo JK, Hogan NM, et al. HIV-positive women report more lifetime partner violence: findings from a voluntary counseling and testing clinic in Dar es Salaam, Tanzania. Am J Public Health. 2002;92: 1331-1337. (Pubitemid 34815800)
25. Van der Straten A, King R, Grinstead O, et al. Sexual coercion, physical violence, and HIV infection among women in steady relationships in Kigali, Rwanda. AIDS Behav. 1998;2:61-73. (Pubitemid 28180448)
26. Macaluso M, Blackwell R, Jamieson DJ, et al. Efficacy of the male latex condom and of the female polyurethane condom as barriers to semen during intercourse: a randomized clinical trial. Am J Epidemiol. 2007; 166:88-96. (Pubitemid 47234293)
27. Schwartz JL, Barnhart K, Creinin MD, et al. Comparative crossover study of the PATH Woman's Condom and the FC Female Condom. Contraception. 2008;78:465-473.
28. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990;80:460-462. (Pubitemid 20105954)
29. Pettifor A, McCoy SI, Padian N. Paying to prevent HIV infection in young women? Lancet. 2012. E-pub ahead of print.
30. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet. 2011;378:269-278.
31. Padian NS, McCoy SI, Balkus JE, et al. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010;24:621-635.
32. Padian NS, Buve A, Balkus J, et al. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;372: 585-599.
33. UNAIDS. World AIDS Day Report. Geneva, Switzerland: UNAIDS; 2011. Available at: http://www.unaids.org/en/resources/publications/ unaidspublications/2011/. Accessed February 15, 2012.
34. Merson M, Padian N, Coates TJ, et al. Combination HIV prevention. Lancet. 2008;372:1805-1806.
35. Piot P, Bartos M, Larson H, et al. Coming to terms with complexity: a call to action for HIV prevention. Lancet. 2008;372:845-859.
36. Padian NS, Holmes CB, McCoy SI, et al. Implementation science for the US President's Emergency Plan for AIDS Relief (PEPFAR). J Acquir Immune Defic Syndr. 2011;56:199-203.
37. Padian NS, McCoy SI, Manian S, et al. Evaluation of large-scale combination HIV prevention programs: essential issues. J Acquir Immune Defic Syndr. 2011;58:E23-E28.
38. The United States President's Emergency Plan for AIDS Relief: Five-Year Strategy. December 2009. Available at: http://www.pepfar.gov/. Accessed February 15, 2012.
39. PEPFAR Scientific Advisory Board. Recommendations for the Office of the US Global AIDS Coordinator: Implications of HPTN 052 for PEPFAR's Treatment Programs. Washington, DC: PEPFAR; 2011. Available at: www.pepfar.gov/documents/ organization/177126.pdf. Accessed February 15, 2012.
40. PEPFAR. Prevention of Mother-to-Child Transmission of HIV: Expert Panel Report and Recommendations to the U.S. Congress and U.S. Global AIDS Coordinator. Washington, DC: PEPFAR; 2010. Available at: http://www.pepfar.gov/ progress/pmtctpanel/index.htm. Accessed February 15, 2012.
41. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:e1001056.
42. Stringer EM, Chi BH, Chintu N, et al. Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries. Bull World Health Organ. 2008;86:57-62.
43. Monitoring and Evaluation to Assess and Use Results Demographic and Health Surveys (MEASURE DHS) Project. HIV/AIDS Survey Indicators Database database online. Calverton, MD: MEASURE DHS; 2011.
44. Bateganya MH, Abdulwadud OA, Kiene SM. Home-based HIV voluntary counseling and testing in developing countries. Cochrane Database Syst Rev. 2007:CD006493.
45. Sweat M, Morin S, Celentano D, et al. Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis. 2011;11:525-532.
46. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802. (Pubitemid 29415583)
47. World Health Organization (WHO). Progress in Scale-Up of Male Circumcision for HIV Prevention in Eastern and Southern Africa: Focus on Service Delivery. Geneva, Switzerland: WHO and UNAIDS; 2011. Available at: http://www.who.int/hiv/pub/malecircumcision/mc-country-progress2011/en/index. html. Accessed February 15, 2012.
48. Katzenstein D, Koulla-Shiro S, Laga M, et al. Learning and doing: operational research and access to HIV treatment in Africa. AIDS. 2010;24(suppl 1):S1-S4.
49. World Health Organization (WHO). Considerations for implementing models for optimizing the volume and efficiency of male circumcision services. Field testing edition, February 2010. Geneva, Switzerland: WHO; 2010. Available at http://www.malecircumcision.org/programs/documents/mc-MOVE-2010-web.pdf. Accessed February 15, 2012.
50. Schwartlander B, Stover J, Hallett T, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377:2031-2041.
51. Galarraga O, Colchero MA, Wamai RG, et al. HIV prevention costeffectiveness: a systematic review. BMC Public Health. 2009;9 (suppl 1):S5.